HOME >> MEDICINE >> NEWS
Aspirin within two days of ischemic stroke reduces deaths

DALLAS, July 9 Giving patients aspirin within 48 hours of the onset of an acute ischemic stroke can reduce death and severity of stroke, according to a joint scientific statement from the American Stroke Association and the American Academy of Neurology.

An ischemic stroke is caused by a blood clot and is the most common type of stroke.

The statement, published in the July issues of Stroke: Journal of the American Heart Association, and Neurology, the scientific journal of the American Academy of Neurology, aims to define the roles of drugs such as aspirin which is in a class of drugs called antiplatelet agents that prevent blood clot formation and drugs such as heparin, a type of anticoagulant that slows blood clotting.

The authors conducted a systematic review of the literature, looking primarily for well-designed, large prospective studies in which patients were randomly selected and blinded (they didn't know what type of therapy they were receiving).

They found evidence from the published trials that giving 160 325 mg of aspirin within 48 hours of stroke onset offers a "small but statistically significant" decrease in death rates and disability from stroke. Recommendations on the use of other types of antiplatelet agents, such as clopidogrel and ticlopidine within the first 48 hours of onset could not be made due to insufficient data.

Conversely, anticoagulants have not been shown to reduce death or disability when used within 48 hours.

"There is some evidence that a fixed dose of heparin given subcutaneously might be helpful for preventing recurrent stroke, but the benefit is balanced against the complication of increased hemorrhage. With the net effect, there is no benefit to that treatment. Therefore, we are not recommending that one use a fixed dose of heparin given subcutaneously to prevent stroke recurrence," says neurologist Bruce Coull, M.D., chair of the Joint Stroke Guideline Development Commi
'"/>

Contact: Bridgette Mc Neill
bridgette.mcneill@heart.org
214-706-1135
American Heart Association
8-Jul-2002


Page: 1 2

Related medicine news :

1. Aspirins potential ability to prevent colon polyps may not apply equally to all
2. Aspirin underused to reduce heart disease risk in diabetic women and young adults
3. Long Island Breast Cancer Study data: Aspirin helps protect some women against breast cancer
4. Aspirin use associated with reduced risk of breast cancer
5. Aspirin use may be associated with increased risk of pancreatic cancer
6. Aspirin is most cost effective way to prevent heart disease
7. Aspirin withdrawal may pose risk to coronary patients
8. Aspirin does not reduce effectiveness of ACE inhibitors
9. Aspirin may help prevent pancreatic cancer
10. Aspirins target, the COX-2 enzyme, linked to cancer of the uterus
11. Aspirin steps up as anti-inflammatory for arteries

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Aspirin within two days ischemic stroke reduces deaths

(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: